Brian McCartney

Brian has responsibility to proactively monitor drug pricing reform issues – including legislative, regulatory and administrative actions at the federal and state level – that could impact strategic and business outcomes for McKesson and their customers, partners and other industry stakeholders in the U.S. pharmaceutical value chain. In addition, Brian assesses financial implications for McKesson, and develops strategies and operational solutions to manage risk and drive business value, harnessing the breadth and depth of enterprise assets and capabilities. Brian has been with McKesson for 2 years and has 20 years of pharmaceutical manufacturer experience in government pricing and policy at J&J and AstraZeneca.